On 16 June it was announced that a low-cost, widely available steroid, dexamethasone, had become the first drug to show an improvement in survival in hospitalized patients requiring ventilation. The data came from the large-scale UK Recovery trial, run by the University of Oxford, which is investigating a number of potential treatments including low-dose dexamethasone, the HIV combination lopinavir/ritonavir, and the antimalarial hydroxychloroquine.
Coronavirus Notebook: Dexamethasone Reduces Deaths In Hospitalized COVID-19 Patients
The standout development in this latest Coronavirus Notebook is that the cheap and plentiful steroid dexamethasone has been shown to reduce deaths by a third in ventilated COVID-19 patients in the UK Recovery trial. In other news, there is fresh funding for smaller firms working on potential treatments and vaccines, and a number of organizations have decided to make their research tools and resources available free of charge in return for open publication of any coronavirus-related findings.
More from Europe
More from Geography
• By
The International Council for Harmonisation has consolidated and modernized its existing stability guidelines into one document, and addressed modern stability testing approaches like modeling, bracketing, and matrixing.
• By
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
• By
US CDC’s Advisory Committee on Immunization Practices voted for harmonized meningococcal vaccine recommendations, while hearing updates about Sanofi’s pending supplemental MedQuadfi indication, AstraZeneca’s FluMist self-administration launch plans, and Lyme disease